drugset / Trial / NCT02605525
Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess the efficacy and safety of SM101 in the treatment of Immunoglobulin A nephropathy (IgAN)
Timeline
- Start
- 2015-12-31
- Primary completion
- 2016-11-30
- Completion
- 2016-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VALZIFLOCEPT | Protein / enzyme biologic | 12 mg/kg | Intravenous |
| Subject | VALZIFLOCEPT | Protein / enzyme biologic | 24 mg/kg | Intravenous |